Cite
HARVARD Citation
Mahalingam, D. et al. (2020). Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours. British journal of clinical pharmacology. 86 (9), pp. 1836-1848. [Online].